Tempus AI Stock Jumps After FDA Clearance for Cardiac Imaging Platform

Tempus AI stock surged 12% Thursday morning following the company’s announcement that it received 510(k) clearance from the U.S. Food and Drug Administration for its updated Tempus Pixel cardiac imaging platform.

The regulatory approval enhances the AI-powered device’s capabilities by allowing the generation of T1 and T2 inline maps for cardiac MR image analysis. These maps provide numerical values to cardiac tissue characteristics, helping clinicians detect conditions like fibrosis, inflammation, or edema that might otherwise remain undetected.

Tempus Pixel can now generate these specialized maps directly from raw MRI data, even when the scanner itself doesn’t produce them, creating detailed DICOM maps for comprehensive tissue assessment.

"This marks another important regulatory milestone for Tempus and underscores our commitment to advancing AI-driven imaging technology that is both scientifically rigorous and clinically meaningful," said Chris Scotto DiVetta, Senior Vice President of AI Applications at Tempus.

The company has been expanding its AI capabilities in medical imaging through strategic acquisitions, including Arterys in 2022 and more recently Paige, an AI company specializing in digital pathology. These acquisitions have brought additional datasets and technologies to strengthen Tempus’ platform offerings in precision medicine.